Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**TetraLens** is an investigational, tetracaine hydrochloride-releasing therapeutic bandage contact lens intended to provide short-term topical ocular analgesia after photorefractive keratectomy. The drug-device product uses a methafilcon A bandage contact lens as a sustained local delivery vehicle for tetracaine, an ester local anesthetic that reversibly blocks voltage-gated sodium channels in sensory nerves, reducing neuronal sodium influx and preventing pain-signal initiation and conduction. A randomized, single-center Early Phase 1 study sponsored by Vance Thompson Vision evaluated one-eye use of TetraLens for six postoperative days versus a contralateral control lens in patients undergoing PRK. ([clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06085352))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on TetraLens.